2010
DOI: 10.1016/j.ijrobp.2009.04.036
|View full text |Cite
|
Sign up to set email alerts
|

Involved Field Radiation After Autologous Stem Cell Transplant for Diffuse Large B-Cell Lymphoma in the Rituximab Era

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
21
0
3

Year Published

2011
2011
2021
2021

Publication Types

Select...
6
2
2

Relationship

1
9

Authors

Journals

citations
Cited by 38 publications
(24 citation statements)
references
References 28 publications
0
21
0
3
Order By: Relevance
“…37 For this reason, many favor either the BEAM or CBV regimen as a standard approach, with the possible addition of localized radiation therapy in sites of persistent disease. 38 A major focus over the past several years to improving standard conditioning has been the incorporation of radioimmunotherapy (RIT). RIT represents a rational alterative to TBI, providing targeted radiotherapy before transplantation while sparing normal structures.…”
Section: High-dose Therapy and Asctmentioning
confidence: 99%
“…37 For this reason, many favor either the BEAM or CBV regimen as a standard approach, with the possible addition of localized radiation therapy in sites of persistent disease. 38 A major focus over the past several years to improving standard conditioning has been the incorporation of radioimmunotherapy (RIT). RIT represents a rational alterative to TBI, providing targeted radiotherapy before transplantation while sparing normal structures.…”
Section: High-dose Therapy and Asctmentioning
confidence: 99%
“…For this group of patients, salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) is a common treatment approach. Radiation therapy to sites of recurrent or refractory disease may enhance local disease control (28)(29)(30)(31). An example is shown in Figure 4.…”
Section: Refractory and Recurrent Aggressive Nhlmentioning
confidence: 99%
“…10 Nevertheless, RT appears to be beneficial in terms of local control whether it is administered before or after ASCT, sometimes with a positive impact on PFS 6 and OS. 8 The main advantage of RT is improvement of local control, resulting in a significant reduction in the relapse rate at the primary site of the disease, especially in the context of residual mass after chemotherapy 6,9 or bulky sites. 15 This advantage is maintained even in the age of anti-CD20 antibodies.…”
Section: Rt In Per-asct Strategymentioning
confidence: 99%